Innodata Inc vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Innodata Inc trades at $62 (market cap $2.10B), while Nuvation Bio Inc. Class A Common Stock trades at $4.98 (market cap $1.74B). The key difference: Innodata Inc is the larger of the two by market cap, and Innodata Inc is more actively traded (989,493 versus 9,289,619). Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| INOD | NUVB | |
|---|---|---|
Market Cap | $2.10B | $1.74B |
Volume | 989,493 | 9,289,619 |
Sector | Technology | Health |
52-Week High | $121.50 | $9.54 |
52-Week Low | $34.45 | $3.41 |
Typical Hold Time | 19 Days | 1 Days |
Enterprise Value | $1.86B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
INOD trades at $61.54, down 2.96% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consecutive earnings beats, with Q1 2026 EPS of $0.42 significantly exceeding the $0.13 estimate, and demonstrated robust revenue growth from $252M in 2025 to $317M projected for 2026. Analyst sentiment remains positive with a 67% buy rating, though the stock faces valuation concerns with a P/E of 47.4.
The outlook for INOD is mixed: strong AI-driven revenue growth and expanding margins support upside potential, but high valuation multiples and bearish technical signals present near-term risks. Investor focus should remain on execution of new initiatives like the motion-capture AI lab and customer diversification efforts to justify premium pricing.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →